Full text is available at the source.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used in patients with obesity and type 2 diabetes undergoing elective spine surgery.
- GLP-1 RAs may improve metabolic risk profiles in patients with obesity and type 2 diabetes.
- The associations of GLP-1 RAs with spinal fusion outcomes are not fully established.
- Perioperative complications related to the use of GLP-1 RAs remain incompletely defined.
- Procedure-specific outcomes for patients on GLP-1 RAs during elective spine surgery need further investigation.
Simplified